Biomarkers for Addiction Treatment Development, 3rd ISAM-NIG Webinar

3rd ISAM Neuroscience Interest Group (ISAM-NIG) Webinar in Collaboration with ENIGMA Addiction Working Group

Biomarkers for Addiction Treatment Development: fMRI Drug Cue Reactivity as an Example

Thursday, October 29th, 2020, 3.00 PM – 5:00 PM (ET, New York Time)

Agenda Introduction and overview of the Webinar (Webinar co-hosts: Hugh Garavan, Antonio Verdejo-García, Anna Zilverstand, Hamed Ekhtiari)

Biomarkers and Biotypes of Drug Addiction: funding opportunities at NIDA and Q&A, Tanya Ramey (NIDA, US)

Neuroimaging-based Biomarker Development for Clinical Trials, Owen Carmicheal (Pennington Biomedical Research Center, USA)

ENIGMA-Addiction Cue Reactivity Initiative (ACRI) and Checklist, Hamed Ekhtiari (Laureate Institute for Brain Research, USA)

ENIGMA-ACRI Checklist: Participant Characteristics, General fMRI Information, General Task Information, Cue Information, Task-related Assessments, Pre-Post Scanning Consideration (James Prisciandaro, Medical University of South Carolina, USA; Marc Kaufman, McLean Hospital/Harvard Medical School, USA; Anna Zilverstand, University of Minnesota; Torsten Wüstenberg, Charité Medical University Berlin, Germany; Falk Kiefer, University of Heidelberg, Germany; Amy Janes, Harvard Medical School, USA)

How to Add fMRI Drug Cue Reactivity to the ENIGMA Consortium: Road Ahead, Hugh Garavan, University of Vermont)

Next Steps

Q&A and discussion

Meeting Wrap Up and Next Steps